(Q40499021)

21 September 2017

Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients (English)

1 reference

21 September 2017

1 reference

M Martinot-Peignoux

1

1 reference

21 September 2017

M Lapalus

2

1 reference

21 September 2017

S Maylin

3

1 reference

21 September 2017

N Boyer

4

1 reference

21 September 2017

C Castelnau

5

1 reference

21 September 2017

N Giuily

6

1 reference

21 September 2017

M Pouteau

7

1 reference

21 September 2017

R Moucari

8

1 reference

21 September 2017

T Asselah

9

1 reference

21 September 2017

P Marcellin

10

1 reference

21 September 2017

4 July 2016

1 reference

Journal of Viral Hepatitis

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

11

1 reference

21 September 2017

905-911

1 reference

Chronic hepatitis B: update 2009

21 September 2017

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

21 January 2018

1 reference

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely

21 January 2018

1 reference

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

21 January 2018

1 reference

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir

21 January 2018

1 reference

Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

21 January 2018

1 reference

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

21 January 2018

1 reference

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.

21 January 2018

1 reference

Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B.

21 January 2018

1 reference

Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Reduction of HBV replication prolongs the early immunological response to IFNα therapy

21 January 2018

1 reference

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

21 January 2018

1 reference

Patient-centric trials for therapeutic development in precision oncology.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

21 January 2018

1 reference

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12565

1 reference

21 September 2017

1 reference